Establishing a standardized therapeutic testing protocol for spinal muscular atrophy
- 30 November 2006
- journal article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 24 (2), 286-295
- https://doi.org/10.1016/j.nbd.2006.07.004
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophyJCI Insight, 2004
- Bipolar DisorderNew England Journal of Medicine, 2004
- Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophyHuman Molecular Genetics, 2003
- Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult ratsBrain Research, 2003
- Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse modelHuman Molecular Genetics, 2002
- Treatment of spinal muscular atrophy by sodium butyrateProceedings of the National Academy of Sciences of the United States of America, 2001
- Deletion of Murine SMN Exon 7 Directed to Skeletal Muscle Leads to Severe Muscular DystrophyThe Journal of cell biology, 2001
- The Neurobiology of Childhood Spinal Muscular AtrophyNeurobiology of Disease, 1996
- Antiepileptic DrugsNew England Journal of Medicine, 1996
- A hungarian study on Werdnig-Hoffmann disease.Journal of Medical Genetics, 1989